Byondis
Robert Kingma is an experienced professional in the operations and research sectors, currently serving as Director Operations and Head of Operations at Byondis since December 2022. Previously, Robert held managerial and project management roles at Bilthoven Biologicals from December 2012 to November 2022, focusing on manufacturing science and technology as well as research and development. Earlier experience includes a position as Trainer at NVI from November 2008 to November 2012, and a brief role as Research Technician at Schering-Plough Research Institute in 2008. Robert began a career in research at NVI from February 2003 to July 2008, working as Senior Research Technician and Research Technician. Robert Kingma earned a Bachelor of Applied Science in Microbiology from HU University of Applied Sciences Utrecht between 2000 and 2003.
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.